{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:20:58Z","timestamp":1787696458315,"version":"build-2784847793"},"reference-count":22,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":40,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.clinthera.2021.10.014","type":"journal-article","created":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T08:19:50Z","timestamp":1637914790000},"page":"2136-2145.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of Lanreotide Autogel in the Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction: A Prospective Phase II Study"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7968-1563","authenticated-orcid":false,"given":"Lionel","family":"Duck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauthier","family":"Demolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"D'Hondt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Dopchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Hendrickx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9671-6534","authenticated-orcid":false,"given":"Beatrice","family":"Lannoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Bastin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Lossignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ossama","family":"Hamdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem","family":"Lybaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8058-7849","authenticated-orcid":false,"given":"Vincent","family":"Vandenhaute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Regnault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"De Ruyter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1003-666X","authenticated-orcid":false,"given":"Karen","family":"Geboes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.10.014_bib0001","doi-asserted-by":"crossref","unstructured":"Tuca A, Guell E, Martinez-Losada E, Codorniu N. Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution. Cancer Manag Res. June 2012:159.","DOI":"10.2147\/CMAR.S29297"},{"key":"10.1016\/j.clinthera.2021.10.014_bib0002","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amsu.2015.07.018","article-title":"Management of intestinal obstruction in advanced malignancy","volume":"4","author":"Ferguson","year":"2015","journal-title":"Ann Med Surg"},{"key":"10.1016\/j.clinthera.2021.10.014_bib0003","first-page":"223","article-title":"Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer","volume":"9","author":"Ripamonti","year":"2001","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2021.10.014_bib0004","article-title":"Safety and Efficacy of Venting Gastrostomy in Malignant Bowel Obstruction: A Systematic Review","author":"Thampy","year":"2019","journal-title":"J Palliat Care"},{"key":"10.1016\/j.clinthera.2021.10.014_bib0005","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JOP.2017.022210","article-title":"Management of Malignant Bowel Obstruction Associated With GI Cancers","volume":"13","author":"Franke","year":"2017","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.clinthera.2021.10.014_bib0006","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3949\/ccjm.78a.10052","article-title":"Malignant bowel obstruction: Individualized treatment near the end of life","volume":"78","author":"Soriano","year":"2011","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.clinthera.2021.10.014_bib0007","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jpainsymman.2016.05.032","article-title":"Somatostatin Analogues Compared With Placebo and Other Pharmacologic Agents in the Management of Symptoms of Inoperable Malignant Bowel Obstruction: A Systematic Review","volume":"52","author":"Obita","year":"2016","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clinthera.2021.10.014_bib0008","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/003655298750026642","article-title":"Somatostatin and the Gastrointestinal Tract","volume":"33","author":"Tulassay","year":"1998","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.clinthera.2021.10.014_bib0009","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0026-0495(90)90214-W","article-title":"Mechanism of action of somatostatin: an overview of receptor function and studies of the molecular characterization and purification of somatostatin receptor proteins","volume":"39","author":"Patel","year":"1990","journal-title":"Metabolism"},{"key":"10.1016\/j.clinthera.2021.10.014_bib0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1385\/ENDO:14:1:029","article-title":"Somatostatin octapeptides (lanreotide, octreotide, vapreotide, and their analogs) share the growth hormone-releasing peptide receptor in the human pituitary gland","volume":"14","author":"Deghenghi","year":"2001","journal-title":"Endocrine"},{"key":"10.1016\/j.clinthera.2021.10.014_bib0011","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1200\/JCO.2011.40.5712","article-title":"Symptomatic Treatment With Lanreotide Microparticles in Inoperable Bowel Obstruction Resulting From Peritoneal Carcinomatosis: A Randomized, Double-Blind, Placebo-Controlled Phase III Study","volume":"30","author":"Mariani","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2021.10.014_bib0012","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1684\/bdc.2011.1535","article-title":"SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction","volume":"99","author":"Laval","year":"2012","journal-title":"Bull Cancer"},{"key":"10.1016\/j.clinthera.2021.10.014_bib0013","unstructured":"Ipsen Ltd. Somatuline Autogel 60 mg, 90mg, or 120mg solution for injection in a prefilled syringe. https:\/\/www.medicines.org.uk\/emc\/product\/4808\/. Published 2018."},{"key":"10.1016\/j.clinthera.2021.10.014_bib0014","unstructured":"Lanreotide. https:\/\/www.drugbank.ca\/drugs\/DB06791. Published 2010."},{"key":"10.1016\/j.clinthera.2021.10.014_bib0015","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1210\/jc.2013-3318","article-title":"Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial","volume":"99","author":"Caron","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2021.10.014_bib0016","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2021.10.014_bib0017","first-page":"675","article-title":"The Edmonton symptom assessment system\u2014what do patients think?","volume":"17","author":"Watanabe","year":"2009","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2021.10.014_bib0018","doi-asserted-by":"crossref","first-page":"M139","DOI":"10.1093\/geronj\/46.4.M139","article-title":"The Use of the Karnofsky Performance Scale in Determining Outcomes and Risk in Geriatric Outpatients","volume":"46","author":"Crooks","year":"1991","journal-title":"J Gerontol"},{"key":"10.1016\/j.clinthera.2021.10.014_bib0019","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/pon.1996","article-title":"The Edmonton Symptom Assessment System, a proposed tool for distress screening in cancer patients: development and refinement","volume":"21","author":"Watanabe","year":"2012","journal-title":"Psychooncology"},{"key":"10.1016\/j.clinthera.2021.10.014_bib0020","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jpainsymman.2014.09.013","article-title":"Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction","volume":"49","author":"Currow","year":"2015","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clinthera.2021.10.014_bib0021","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4158\/EP151172.OR","article-title":"Evaluation of Lanreotide depot\/autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): a randomized, double-blind, placebo-controlled trial","volume":"22","author":"Vinik","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1016\/j.clinthera.2021.10.014_bib0022","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1634\/theoncologist.2017-0284","article-title":"Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot\/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study","volume":"23","author":"Fisher","year":"2018","journal-title":"Oncologist"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821004525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821004525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:56:38Z","timestamp":1758963398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821004525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0149291821004525"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.10.014","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Lanreotide Autogel in the Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction: A Prospective Phase II Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}